June 23, 2016 12:18 PM EDTUpdated November 1, 12:18 PM
Bioregnum
Special
Opinion

These 300(+) Biotech Twit­ter cit­i­zens are the quick­est to tweet news

Bioreg­num

by Ar­salan Arif
Like many of you, I have a com­pli­cat­ed re­la­tion­ship with Twit­ter. I don’t feel good at it, but here …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times